NCI-MATCH, also known as National Cancer Institute-Molecular Analysis for Therapy Choice, or study EAY131, is a phase II precision medicine trial that seeks to determine whether matching certain drugs or drug combinations in adults whose tumors have specific gene abnormalities will effectively treat their cancer, regardless of their cancer type. Such discoveries could be eligible to move on to larger, more definitive trials.
NCI-MATCH (EAY131) was co-developed by the ECOG-ACRIN Cancer Research Group and the National Cancer Institute. It is being led by ECOG-ACRIN through its Biomarker Sciences Program.
Listed below is general information to assist research personnel who are interested in participating in the study.
To participate in this trial, medical facilities (sites) must meet ALL of the criteria listed below.
EAY131 is the master protocol identification (ID) for the overall trial. Each treatment/genetic abnormality being studied in this trial is a substudy (or subprotocol) of EAY131. The subprotocols are identified with additional letters and numbers added to the end of the master protocol ID; EAY131-A, for example. All subprotocols must be used in conjunction with the master protocol, EAY131.
The master protocol and all subprotocol documents, along with related material, are password protected. Research personnel may access the documents on the NCI Cancer Trial Support Unit (CTSU) website.
ECOG-ACRIN members, please use the Member Login button at the top of this page to access the documents. For assistance with login credentials, call the ECOG-ACRIN Operations Office in Boston at 857-504-2900 during normal business hours.
NCI-MATCH (EAY131) opened to patient enrollment on August 12, 2015 with the master protocol and ten subprotocols. Additional subprotocols were added on a rolling basis through amendments to the master protocol. View the NCI-MATCH Active Trials Table.
Effective May 11, 2017, there is a new process to identify potentially eligible patients at participating sites through genomic tumor sequencing that is performed by designated commercial and academic laboratories. To learn more, visit the Patient Eligibility Overview section.
In this trial, investigators register patients via the NCI Oncology Patient Enrollment Network (OPEN) Registration System, which is accessible 24 hours a day, seven days a week at the CTSU website.
NCI-MATCH (EAY131) is being conducted exclusively in Medidata Rave®. There are no paper case report forms for this trial. Clinical research associates (CRAs) at the sites enter data directly into Rave at The ECOG-ACRIN Data Management Team performs central office data management in Rave.
This clinical trial requires research personnel at participating institutions to complete training prior to starting data entry. Medidata Rave® assigns training courses as eLearnings. Listed below are the required eLearnings that pertain to NCI-MATCH (EAY131):
Required for CRAs performing data entry in Rave:
Required for Principal Investigators and Study Chairs performing sign off on case report forms in Rave:
Optional eLearnings for all:
Inquiries about the NCI-MATCH (EAY131) study may be directed to:
ECOG-ACRIN Cancer Research Group
Operations Office – Boston
|Trial Educational Materials|
|NCI-MATCH / EAY131 for Researchers|
|ECOG Performance Status|